| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We searched for the candidates of recurrence risk stratification markers of Stage II/III gastric cancer by quantitative PCR method and exploratory proteomics. 13 genes were identified by the quantitative PCR method, and 4 proteins were identified by exploratory proteomics. Then we examined the expression of these marker candidates by immunostaining using tissue microarray, it was possible to stratify the risk of recurrence with the combination of SPARC, EZH2, ERBB2, p53.
In development of small molecular anticancer drugs targeting KIAA 1199, it was narrowed down to 12 kinds of drugs due to the antitumor effect on gastric cancer cells. We then examinied the effect of combination with 5-FU on gastric cancer by Chou and Talaly method, synergistic effect was confirmed in one drug.We are planning to conduct animal experiments using this drug.
|
